XL 844

Drug Profile

XL 844

Alternative Names: EXEL-9844; XL844

Latest Information Update: 17 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class Antineoplastics
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Checkpoint kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia

Most Recent Events

  • 17 Dec 2008 Discontinued - Phase-I for Cancer in USA (PO)
  • 17 Dec 2008 Discontinued - Phase-I for Chronic lymphocytic leukaemia in USA (PO)
  • 23 Oct 2008 GlaxoSmithKline decides not to license XL 844
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top